NASDAQ: KRYSKrystal Biotech Inc Stock
$197.42+0.51 (+0.26%)
Updated Nov 29, 2024
KRYS Price
$197.42
Fair Value Price
$28.42
Market Cap
$5.68B
52 Week Low
$100.98
52 Week High
$219.34
P/E
107.29x
P/B
6.41x
P/S
21.64x
PEG
2x
Dividend Yield
N/A
Revenue
$241.52M
Earnings
$52.37M
Gross Margin
92.6%
Operating Margin
23.77%
Profit Margin
21.7%
Debt to Equity
0.11
Operating Cash Flow
$63M
Beta
1.39
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KRYS Overview
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KRYS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
D
Sentiment
F
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KRYS
Ranked#73 of 340
Ranked#73 of 340
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.61 | A | |
| $7.72 | A | |
| $57.68 | A |
Be the first to know about important KRYS news, forecast changes, insider trades & much more!
KRYS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KRYS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRYS ($197.42) is overvalued by 594.6% relative to our estimate of its Fair Value price of $28.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KRYS ($197.42) is not significantly undervalued (594.6%) relative to our estimate of its Fair Value price of $28.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KRYS ($197.42) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRYS due diligence checks available for Premium users.
Valuation
KRYS fair value
Fair Value of KRYS stock based on Discounted Cash Flow (DCF)
Price
$197.42
Fair Value
$28.42
Overvalued by
594.60%
KRYS ($197.42) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRYS ($197.42) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRYS ($197.42) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRYS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
107.29x
Industry
-107.59x
Market
27.74x
KRYS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KRYS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
KRYS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.41x
Industry
5.61x
KRYS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRYS price to earnings growth (PEG)
For valuing profitable companies with growth potential
KRYS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
KRYS's financial health
Profit margin
Revenue
$83.8M
Net Income
$27.2M
Profit Margin
32.4%
KRYS's Earnings (EBIT) of $57.40M... subscribe to Premium to read more.
Interest Coverage Financials
KRYS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$982.3M
Liabilities
$96.5M
Debt to equity
0.11
KRYS's short-term assets ($713.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRYS's short-term assets ($713.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRYS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KRYS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$58.9M
Investing
-$34.3M
Financing
$3.4M
KRYS's operating cash flow ($63.35M)... subscribe to Premium to read more.
Debt Coverage Financials
KRYS vs Biotech Stocks
Krystal Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.